OHSU startup, Inherent Targeting, is among the Pacific Northwest-based startups selected to present at the Pacific Northwest Startup Showcase & Social on Tuesday, October 12 from 10am-12pm.
Inherent Targeting improves surgical outcomes with high contrast, nerve-specific fluorescent dyes that help surgeons visualize buried nerves and distinguish them from surrounding tissue. This reduces patient pain, loss of function, and long-term physical impairment. Dr. Summer Gibbs and her team (pictured here) developed the novel dyes that are the basis of this technology.
The Inherent Targeting team has received guidance, support, and resources from OHSU offices of Technology Transfer, Collaborations and Entrepreneurship, and the Oregon Clinical and Translational Research Institute (OCTRI). In 2018, they graduated from OCTRI’s BIP Corp, an I-Corps commercialization readiness course, and in 2019 were awarded an OCTRI Biomedical Innovation Program pilot award. Since then, Inherent Targeting has been featured in elite research publications (Science Translational Medicine) and startup competitions. They were awarded a $2.25M NIH Small Business Innovation Research grant earlier this year.
- Biomedical innovation research
Oregon Health and Science University
CTSA Program In Action Goals
Goal 1: Train and Cultivate the Translational Science Workforce
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials